As of Jun 16, 2024, Amgen's P/S ratio stood at 4.91, a 20.05% change from the 4.09 P/S ratio recorded in the previous year.

The Amgen P/S history

Amgen Aktienanalyse

What does Amgen do?

Amgen Inc. is a global biotechnology company focused on the development and production of pharmaceuticals. It was founded in 1980 by William K. Bowes Jr. and George B. Rathmann in Thousand Oaks, California/USA. The founders had the vision to create new treatment options for serious diseases such as cancer, autoimmune diseases, and osteoporosis. Amgen faced difficulties in its early days due to limited financial resources and setbacks in research. However, the company succeeded in developing the first recombinant therapeutic protein drug, Erythropoietin (EPO), and bringing it to the market. Today, Amgen has become one of the largest biotechnology companies in the world with over 24,000 employees worldwide. The company is known for its research and development work in oncology, kidney diseases, blood disorders, inflammation, and bone diseases. Amgen's business model involves investing in research and development to develop new drugs and commercialize them in global markets. The company follows a "biological platform" strategy, focusing on biotechnology products based on proteins and antibodies. Amgen has several product lines, including Biologics, Biosimilars, and Small Molecules. Biologics are protein-based drugs manufactured using living cells. Biosimilars are products that have similar structures to existing biologics. Small Molecules are chemically manufactured drugs. Some of Amgen's most well-known products include Epogen and Aranesp (both Erythropoietin-releasing hormones), Neulasta and Neupogen (both granulocyte colony-stimulating factors), Enbrel (a TNF inhibitor for the treatment of rheumatoid arthritis), Prolia and Xgeva (both Denosumab inhibitors for the treatment of osteoporosis), and Blincyto (a bispecific antibody against cancer). Amgen is also involved in cancer immunotherapy and has a range of medications in its portfolio, including a CAR-T immunotherapy used for certain forms of acute lymphoblastic leukemia (ALL). In addition, Amgen specializes in the development of biosimilars. In 2017, the company introduced six biosimilars to the market, including copies of Enbrel and Humira for the treatment of rheumatoid arthritis. Biosimilars have the potential to reduce the costs of patient treatment as they are typically cheaper than the original products. Furthermore, Amgen works closely with other companies and research institutions to develop innovative products and technologies. The company has numerous partnerships and licensing agreements with other companies in the biotech industry to accelerate its growth and expand its product pipeline. Overall, Amgen has successfully established itself as one of the leading biotechnology companies in the world. It is known for its innovative products, investments in research and development, and partnerships with other companies. With its wide product portfolio and commitment to producing high-quality biological products, Amgen will continue to play an important role in the healthcare industry. Amgen ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Amgen revenue by segment

In the annual report of the Amgen share (US0311621009, 867900, AMGN), it breaks down its revenues into 2 segments: 1. Human Therapeutics, 2. Other. The Amgen stock (WKN: 867900, ISIN: US0311621009, Ticker Symbol: AMGN) is a leading investment for investors interested in participating in the Health Care sector.

  • 95 % Human Therapeutics

  • 5 % Other

P/S Details

Decoding Amgen's P/S Ratio

Amgen's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Amgen's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Amgen's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Amgen’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Amgen Stock

What is the price-to-earnings ratio of Amgen?

The price-earnings ratio of Amgen is currently 4.91.

How has the price-earnings ratio of Amgen changed compared to last year?

The price-to-earnings ratio of Amgen has increased by 20.05% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Amgen high compared to other companies?

Yes, the price-to-earnings ratio of Amgen is high compared to other companies.

How does an increase in the price-earnings ratio of Amgen affect the company?

An increase in the price-earnings ratio of Amgen would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Amgen affect the company?

A decrease in the price-earnings ratio of Amgen would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Amgen?

Some factors that influence the price-earnings ratio of Amgen are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Amgen pay?

Over the past 12 months, Amgen paid a dividend of 8.52 USD . This corresponds to a dividend yield of about 2.85 %. For the coming 12 months, Amgen is expected to pay a dividend of 14.1 USD.

What is the dividend yield of Amgen?

The current dividend yield of Amgen is 2.85 %.

When does Amgen pay dividends?

Amgen pays a quarterly dividend. This is distributed in the months of September, December, March, June.

How secure is the dividend of Amgen?

Amgen paid dividends every year for the past 19 years.

What is the dividend of Amgen?

For the upcoming 12 months, dividends amounting to 14.1 USD are expected. This corresponds to a dividend yield of 4.72 %.

In which sector is Amgen located?

Amgen is assigned to the 'Health' sector.

Wann musste ich die Aktien von Amgen kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Amgen from 6/7/2024 amounting to 2.25 USD, you needed to have the stock in your portfolio before the ex-date on 5/16/2024.

When did Amgen pay the last dividend?

The last dividend was paid out on 6/7/2024.

What was the dividend of Amgen in the year 2023?

In the year 2023, Amgen distributed 7.76 USD as dividends.

In which currency does Amgen pay out the dividend?

The dividends of Amgen are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Amgen stock can be added to a savings plan with the following providers: Trade Republic, Scalable Capital and Consorsbank

Andere Kennzahlen von Amgen

Our stock analysis for Amgen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Amgen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.